Biotech companies spend a lot of money. They spend it on research and development, clinical trials, and (if they are lucky) marketing and a salesforce. Bringing a new pharmaceutical or medical device to market is an expensive proposition. In fact, it's fair to say that a lot of biotech companies bleed cash.
So it's highly unusual to find biotech companies with a cash position that's higher than the company's valuation. Nonetheless, our contributors found three fascinating biotechs that meet that standard. Here's what they think about Invitae (NYSE: NVTA) , Singular Genomics (NASDAQ: OMIC) , and Agenus (NASDAQ: AGEN) .
Image source: Getty Images.
For further details see:
3 Biotech Stocks With a Cash Pile Higher Than Their Valuations